Discovery and Characterization of ACT‐451840: an Antimalarial Drug with a Novel Mechanism of Action
Citations Over TimeTop 10% of 2016 papers
Abstract
More than 40 % of the world's population is at risk of being infected with malaria. Most malaria cases occur in the countries of sub-Saharan Africa, Central and South America, and Asia. Resistance to standard therapy, including artemisinin combinations, is increasing. There is an urgent need for novel antimalarials with new mechanisms of action. In a phenotypic screen, we identified a series of phenylalanine-based compounds that exhibit antimalarial activity via a new and yet unknown mechanism of action. Our optimization efforts culminated in the selection of ACT-451840 [(S,E)-N-(4-(4-acetylpiperazin-1-yl)benzyl)-3-(4-(tert-butyl)phenyl)-N-(1-(4-(4-cyanobenzyl)piperazin-1-yl)-1-oxo-3-phenylpropan-2-yl)acrylamide] for clinical development. Herein we describe our optimization efforts from the screening hit to the potential drug candidate with respect to antiparasitic activity, drug metabolism and pharmacokinetics (DMPK) properties, and in vivo pharmacological efficacy.
Related Papers
- → Artemisinin-Resistant Plasmodium falciparum Parasites Exhibit Altered Patterns of Development in Infected Erythrocytes(2015)122 cited
- → Synthesis and biological evaluation of extraordinarily potent C-10 carba artemisinin dimers against P. falciparum malaria parasites and HL-60 cancer cells(2008)61 cited
- → Mechanism-Based Design of Parasite-Targeted Artemisinin Derivatives: Synthesis and Antimalarial Activity of Benzylamino and Alkylamino Ether Analogues of Artemisinin(1996)28 cited
- Dynamics of multi-drug resistance in Plasmodium falciparum in Thailand.(1992)
- → Analysis of Within-host Evolution of Plasmodium falciparum during treatment with Artemisinin Combination TherapiesAnalysis of Within-host Evolution of Plasmodium falciparum during treatment with Artemisinin Combination Therapies(2019)